Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains.

IF 4.1 2区 医学 Q2 MICROBIOLOGY
Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Jenna Colombo, David A Six, Denis M Daigle, Greg Moeck, Steven A Boyd, Daniel C Pevear
{"title":"Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strains.","authors":"Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Jenna Colombo, David A Six, Denis M Daigle, Greg Moeck, Steven A Boyd, Daniel C Pevear","doi":"10.1128/aac.01699-24","DOIUrl":null,"url":null,"abstract":"<p><p>Cefepime-taniborbactam is a β-lactam/β-lactamase inhibitor combination in clinical development for the treatment of Enterobacterales and <i>Pseudomonas</i> infections, including carbapenem-resistant Enterobacterales and multidrug-resistant <i>Pseudomonas aeruginosa</i>. Taniborbactam is a novel cyclic boronate with direct inhibitory activity against clinically relevant Ambler class A, B, C, and D β-lactamases. To further characterize the spectrum of β-lactamase coverage by cefepime-taniborbactam, we constructed 190 isogenic strains of <i>Escherichia coli</i> that constitutively expressed a different β-lactamase. Synthetic codon-optimized genes encoding the mature periplasmic protein linked to the TEM-1 signal sequence were used for optimized expression and periplasmic localization of the β-lactamase. The repertoire of β-lactamases consisted of 50 Ambler class A, 34 class B (metallo), 48 class C, and 58 class D enzymes known to mediate β-lactam resistance in the clinical isolates of Enterobacterales and <i>P. aeruginosa</i>. Overall, in the 190 isogenic strains, the MIC<sub>50</sub>/MIC<sub>90</sub> values were 8/128 µg/mL for cefepime and >128/>128 µg/mL for ceftazidime. Cefepime-taniborbactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 0.25/8 µg/mL) showed greater activity than ceftazidime-avibactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 4/>128 µg/mL) and similar activity to aztreonam-avibactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 0.5/4 µg/mL). Cefepime-taniborbactam inhibited strains overproducing metallo-β-lactamases, including clinically important NDM and VIM enzymes, whereas ceftazidime-avibactam showed no coverage. Among the 129 β-lactamase-overproducing strains with increased cefepime MIC ≥16-fold relative to the control strain, taniborbactam potentiated cefepime MIC by ≥8-fold for 113 strains overexpressing β-lactamases (42 Ambler class A, 24 B, 23 C, and 24 D). Cefepime-taniborbactam demonstrated broader activity relative to ceftazidime-avibactam and comparable activity with aztreonam-avibactam in the overall coverage of both serine- and metallo-β-lactamases from all four Ambler classes.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0169924"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01699-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cefepime-taniborbactam is a β-lactam/β-lactamase inhibitor combination in clinical development for the treatment of Enterobacterales and Pseudomonas infections, including carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa. Taniborbactam is a novel cyclic boronate with direct inhibitory activity against clinically relevant Ambler class A, B, C, and D β-lactamases. To further characterize the spectrum of β-lactamase coverage by cefepime-taniborbactam, we constructed 190 isogenic strains of Escherichia coli that constitutively expressed a different β-lactamase. Synthetic codon-optimized genes encoding the mature periplasmic protein linked to the TEM-1 signal sequence were used for optimized expression and periplasmic localization of the β-lactamase. The repertoire of β-lactamases consisted of 50 Ambler class A, 34 class B (metallo), 48 class C, and 58 class D enzymes known to mediate β-lactam resistance in the clinical isolates of Enterobacterales and P. aeruginosa. Overall, in the 190 isogenic strains, the MIC50/MIC90 values were 8/128 µg/mL for cefepime and >128/>128 µg/mL for ceftazidime. Cefepime-taniborbactam (MIC50/MIC90 of 0.25/8 µg/mL) showed greater activity than ceftazidime-avibactam (MIC50/MIC90 of 4/>128 µg/mL) and similar activity to aztreonam-avibactam (MIC50/MIC90 of 0.5/4 µg/mL). Cefepime-taniborbactam inhibited strains overproducing metallo-β-lactamases, including clinically important NDM and VIM enzymes, whereas ceftazidime-avibactam showed no coverage. Among the 129 β-lactamase-overproducing strains with increased cefepime MIC ≥16-fold relative to the control strain, taniborbactam potentiated cefepime MIC by ≥8-fold for 113 strains overexpressing β-lactamases (42 Ambler class A, 24 B, 23 C, and 24 D). Cefepime-taniborbactam demonstrated broader activity relative to ceftazidime-avibactam and comparable activity with aztreonam-avibactam in the overall coverage of both serine- and metallo-β-lactamases from all four Ambler classes.

头孢吡肟-他尼巴坦是一种β-内酰胺/β-内酰胺酶抑制剂复方制剂,目前正处于临床开发阶段,用于治疗肠杆菌和假单胞菌感染,包括耐碳青霉烯类肠杆菌和耐多药铜绿假单胞菌。他尼巴坦是一种新型环硼酸盐,对临床相关的安布勒 A、B、C 和 D 类 β-内酰胺酶具有直接抑制活性。为了进一步确定头孢吡肟-他尼巴坦对 β-内酰胺酶的覆盖范围,我们构建了 190 株组成型表达不同 β-内酰胺酶的大肠杆菌异源菌株。编码与 TEM-1 信号序列相连的成熟周质蛋白的合成密码子优化基因被用于优化 β-内酰胺酶的表达和周质定位。β-内酰胺酶谱包括 50 种安布勒 A 类、34 种 B 类(金属)、48 种 C 类和 58 种 D 类酶,已知这些酶介导了肠杆菌属和铜绿假单胞菌临床分离物对β-内酰胺的耐药性。总体而言,在 190 株同源菌株中,头孢吡肟的 MIC50/MIC90 值为 8/128 µg/mL ,头孢他啶的 MIC50/MIC90 值>128/>128 µg/mL。头孢吡肟-他尼巴坦(MIC50/MIC90 为 0.25/8 µg/mL)比头孢唑肟-阿维巴坦(MIC50/MIC90 为 4/>128 µg/mL)显示出更强的活性,而与阿兹曲南-阿维巴坦(MIC50/MIC90 为 0.5/4 µg/mL)的活性相似。头孢吡肟-他尼巴坦可抑制过度产生金属-β-内酰胺酶的菌株,包括临床上重要的 NDM 和 VIM 酶,而头孢唑肟-阿维巴坦则没有覆盖范围。与对照菌株相比,在头孢吡肟 MIC 增加≥16 倍的 129 株过度产生β-内酰胺酶的菌株中,对于 113 株过度表达β-内酰胺酶的菌株(42 株 Ambler A 级、24 株 B 级、23 株 C 级和 24 株 D 级),他尼巴坦可使头孢吡肟 MIC 增效≥8 倍。头孢吡肟-他尼巴坦与头孢唑肟-阿维巴坦相比具有更广泛的活性,而在对所有四个安布勒类的丝氨酸和金属-β-内酰胺酶的总体覆盖范围内,头孢吡肟-他尼巴坦的活性与阿兹曲南-阿维巴坦相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.00
自引率
8.20%
发文量
762
审稿时长
3 months
期刊介绍: Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信